BridgeBio Oncology Therapeutics, Inc. BBOT 深 沪
等待开盘 08-18 09:30:00 美东时间
9.08
+0.020
+0.22%
华盛通- 最 高9.3999
- 今 开8.90
- 成交量 9.91万股
- 最 低 8.90
- 昨 收 9.06
- 总市值 7.27亿
- 52周最高 14.87
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 7.00
- 委 比 92.66%
- 总股本 8010.71万
- 历史最高 14.87
- 量 比 1.11
- 振 幅 5.52%
- 历史最低 7.00
- 每 手 1
- 风险率 1.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
08-15 00:16
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per share from the same period last year.
08-12 04:39
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
07-08 18:09
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.
06-23 01:34
BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
05-13 05:54
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
05-11 19:51
